See more : Candente Copper Corp. (DNT.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Eliem Therapeutics, Inc. (ELYM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eliem Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KNeoMedia Limited (KNEOF) Income Statement Analysis – Financial Results
- Brigade Enterprises Limited (BRIGADE.NS) Income Statement Analysis – Financial Results
- PDG Realty S.A. Empreendimentos e Participações (PDGR3.SA) Income Statement Analysis – Financial Results
- Good Life China Corporation (GLCC) Income Statement Analysis – Financial Results
- Alnylam Pharmaceuticals, Inc. (DUL.DE) Income Statement Analysis – Financial Results
Eliem Therapeutics, Inc. (ELYM)
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 15.41M | 26.21M | 23.32M | 9.34M | 4.02M |
| General & Administrative | 9.89M | 18.92M | 12.35M | 2.43M | 677.00K |
| Selling & Marketing | 24.85M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.89M | 18.92M | 12.35M | 2.43M | 677.00K |
| Other Expenses | 0.00 | 1.38M | -11.64M | 0.00 | 914.00K |
| Operating Expenses | 37.41M | 45.14M | 35.67M | 11.77M | 4.70M |
| Cost & Expenses | 37.41M | 45.14M | 35.67M | 11.77M | 4.70M |
| Interest Income | 0.00 | 1.20K | 450.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.59M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 21.47M | 45.14M | 35.67M | 11.77M | 4.70M |
| EBITDA | -13.65M | -43.65M | -35.50M | -2.87M | -1.93M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.47M | -45.14M | -35.67M | -20.93M | -7.45M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.65M | -109.00K | -11.81M | 257.00K | 899.00K |
| Income Before Tax | -35.12M | -45.24M | -47.48M | -20.67M | -6.55M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -21.47K | 109.00K | -66.56K | -9.16M | -2.75M |
| Net Income | -35.12M | -45.35M | -47.48M | -11.51M | -3.80M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.30 | -1.72 | -1.81 | -0.44 | -0.14 |
| EPS Diluted | -1.30 | -1.72 | -1.81 | -0.44 | -0.14 |
| Weighted Avg Shares Out | 26.99M | 26.31M | 26.24M | 26.32M | 26.32M |
| Weighted Avg Shares Out (Dil) | 26.99M | 26.31M | 26.24M | 26.32M | 26.32M |
Climb Bio to Host Virtual Investor Event on October 15, 2024
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio's management team and an external expert who...
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.
Eliem Therapeutics Announces Additions to its Leadership Team
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D.
Eliem Therapeutics Reports Second Quarter Financial Results
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones...
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034....
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of...
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm
PHILADELPHIA , April 15, 2024 /PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders. The investigation seeks to determine whether Eliem issued false and misleading statements and/or...
ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders. Halper Sadeh encourages Eliem shareholders to click here to learn...
Source: https://incomestatements.info
Category: Stock Reports